Home / Companies / ORCHARD THERAPEUTICS PLC
ORCHARD THERAPEUTICS PLC
How funds and institutional managers reported voting their shares, year to 30 June 2024
- Filers reporting
- 57year to 30 June 2024
- Against management on pay
- 46.3%19 of 41 reporting filers
- Same, by reported shares
- 50.5%shares reported on Form N-PX
- Meetings on file
- 1across 1 season
foragainstabstain, withhold or otheramber tick: the portion cast against management
57 Form N-PX filers reported votes at ORCHARD THERAPEUTICS PLC for the year to 30 June 2024, across one meeting.
On the advisory vote on executive pay, 19 of the 41 filers that reported a position voted against management (46.3%), 38.9 percentage points above the median company on this site (7.5%). By reported shares the figure is 50.5% (median 2.9%). These are shares of the filers reporting on Form N-PX, not of all votes cast at the meeting.
Among the largest fund families, 1 voted with management on pay and 4 voted against: Fidelity, Columbia Threadneedle, Vanguard and Federated Hermes.
Meetings
| Meeting date | Season | Filers reporting | Items | Against management on pay |
|---|---|---|---|---|
| 19 Dec 2023 | year to 30 June 2024 | 56 | 5 | 46.3% |
Meetings with 20 or more reporting filers have their own page with every item. Dates are as filers typed them; dates up to three days apart are treated as one meeting.
Say-on-pay: this company and the median
| year to 30 June 2024 | ORCHARD THERAPEUTICS PLC | Median company |
|---|---|---|
| Reporting filers voting against management | 46.3% | 7.5% |
| Reported shares voted against management | 50.5% | 2.9% |
Among filers reporting on Form N-PX. The median is over 3,781 companies with a say-on-pay item reported by 20 or more filers.
How the largest families voted
Meeting of 19 Dec 2023: say-on-pay and each shareholder proposal that could be told apart.
| Family | Say-on-pay |
|---|---|
| Vanguard | Against * |
| Fidelity | Against * |
| Goldman Sachs | Split or no vote |
| Columbia Threadneedle | Against * |
| Federated Hermes | Against * |
| Neuberger Berman | For |
* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.
By season
| Season | Filers reporting | Against management on pay, filers | By reported shares | Say-on-pay split |
|---|---|---|---|---|
| year to 30 June 2024 | 57 | 46.3% | 50.5% |
Category mix
Share of the vote records reported for this company, by the category filers chose.
| Category | Vote records | Share |
|---|---|---|
| SECTION 14A SAY-ON-PAY VOTES | 59 | 66.3% |
| EXTRAORDINARY TRANSACTIONS | 12 | 13.5% |
| CAPITAL STRUCTURE | 8 | 9.0% |
| CORPORATE GOVERNANCE | 6 | 6.7% |
| COMPENSATION | 4 | 4.5% |
Questions
How did large funds vote at ORCHARD THERAPEUTICS PLC?
For the year to 30 June 2024, 41 Form N-PX filers reported a say-on-pay vote at ORCHARD THERAPEUTICS PLC; 19 voted against management (46.3%). The table on this page lists the position of each of the largest fund families on say-on-pay and on each shareholder proposal that could be told apart in the filings.
Were there shareholder proposals at ORCHARD THERAPEUTICS PLC?
No proposal from security holders was reported by enough filers to be shown for the year to 30 June 2024.
Is this the meeting result?
No. The figures are shares of the funds and managers that file Form N-PX, and of the shares they reported. Holders that do not file the form (individuals, most foreign investors, insiders) are not included, so the split here can differ widely from the certified result, which ORCHARD THERAPEUTICS PLC reports on Form 8-K.
Where does the data come from?
From Form N-PX filings on the SEC's EDGAR system, grouped by company. Filers type company names and meeting dates themselves; this site groups spellings of the same company and folds meeting dates up to three days apart. Data runs through 30 Sep 2026; the median compares 3,781 companies.
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings that list ORCHARD THERAPEUTICS PLC, grouped by company. The name is the most common spelling among filers. Not verified by the SEC. Filings read through 30 Sep 2026; page built 1 Oct 2026.